Hutchison China Meditech Limited Chi-Med to Announce 2018 Final Results (4760P)

TIDMHCM

RNS Number : 4760P

Hutchison China Meditech Limited

08 February 2019

Chi-Med to Announce 2018 Final Results

London: Friday, February 8, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11, 2019 at 7:00 am Greenwich Mean Time (GMT).

An analyst presentation will be held at 9:00 am GMT (5:00 pm Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (1:00 pm GMT).

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 400 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

 
 Investor Enquiries 
  Mark Lee, Senior Vice President                                [phone] 
  Annie Cheng, Vice President                                    [phone] 
  David Dible, Citigate Dewe Rogerson                            [phone] (Mobile) 
                                                                 [e-mail] 
  Xuan Yang, Solebury Trout                                      [phone] (Mobile) 
                                                                  [e-mail] 
 
 Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson         [phone] (Mobile) 
                                                                  [e-mail] 
  Americas - Brad Miles, Solebury Trout                          [phone] (Mobile) 
                                                                  [e-mail] 
  Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick           [phone] (Mobile) 
                                                                  [e-mail] 
                                                     Zhou Yi,    [phone] (Mobile) 
                                                     Brunswick    [e-mail] 
  Mainland China - Sam Shen, Edelman                             [phone] (Mobile) 
                                                                  [e-mail] 
 
Nominated Advisor 
  Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited       [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NORUGUAAPUPBUQR

(END) Dow Jones Newswires

February 08, 2019 02:00 ET (07:00 GMT)